Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

• Published in: Clinical cancer research Vol. 24; no. 12; pp. 2873 - 2885
• Main Authors: Camblin, Adam J, Pace, Emily A, Adams, Sharlene, Curley, Michael D, Rimkunas, Victoria, Nie, Lin, Tan, Gege, Bloom, Troy, Iadevaia, Sergio, Baum, Jason, Minx, Charlene, Czibere, Akos, Louis, Chrystal U, Drummond, Daryl C, Nielsen, Ulrik B, Schoeberl, Birgit, Pipas, J Marc, Straubinger, Robert M, Askoxylakis, Vasileios, Lugovskoy, Alexey A
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 15.06.2018
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Apoptosis; Bispecific antibodies; Cancer; Cell survival; Chemotherapy; Design factors; Design standards; ErbB-3 protein; Experimental design; Gemcitabine; Growth factors; Heregulin; In vivo methods and tests; Inhibition; Insulin; Insulin-like growth factor I; Insulin-like growth factor I receptors; Insulin-like growth factors; Paclitaxel; Pancreatic cancer; Phosphorylation; Receptors; Screening; Signaling; Tumor cell lines; Xenografts; Xenotransplantation

Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic cancer pathophysiology, promoting cancer cell survival and therapeutic resistance. Assessment of IGF-1R inhibitors in combination with standard-of-care chemotherapy, however, failed to demonstrate significant clinica...